Overview

Study of TNF-Antagonism in the Metabolic Syndrome (II)

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study will investigate whether etanercept will result in improved inflammatory indices, glucose tolerance and endothelial function in patients with the metabolic syndrome.
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Amgen
Treatments:
Etanercept